Health
Biotechnology
Pharmaceutical
Ionis Pharmaceuticals
$78.909876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$78.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.60 (-1.99%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!
About
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
Employees
737
Headquarters
Carlsbad, California
Founded
1989
Market Cap
10.88B
Price-Earnings Ratio
42.68
Dividend Yield
0.00
Average Volume
1.11M
High Today
$80.60
Low Today
$78.52
Open Price
$80.30
Volume
411.58K
52 Week High
$81.03
52 Week Low
$39.07
Collections
Health
Biotechnology
Pharmaceutical
Therapy
Technology
News
Simply Wall StMar 21
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS): Time For A Financial Health Check
There are a number of reasons that attract investors towards large-cap companies such as Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), with a market cap of US$11b. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong and stable investment. But, the key to extending previous success is in the health of the company’s financials. This article will examine Ionis Pharmaceuticals’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downtu...
MarketWatchMar 18
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. Shares of Ionis, which were flat after hours, had closed down 2.1% at $49.78 in regular trading Thursday. Biogen Further Expands Presence in China with Approval of SPINRAZA(R) (nusinersen), the First and Only Tre...
Associated PressMar 15
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that data fro...
Price Paid on Robinhood
49% Higher
Right Now
52 Week Low
$39.07
Average Price Paid
$52.94
52 Week High
$81.03
Earnings
-$0.19
-$0.06
$0.07
$0.20
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 3, Pre-Market